Latest news with #MacularDegeneration
The Hindu
26-05-2025
- Business
- The Hindu
Lupin, SteinCares ink pact to roll out biosimilar for eye disease in Latin America
Drugmaker Lupin has entered into a licence and supply agreement with SteinCares for commercialisation of its biosimilar ranibizumab across Latin America, excluding Mexico and Argentina. SteinCares, which is specialty healthcare company in Latin America, will handle all regulatory filings, registrations and commercialisation of Ranibizumab in LATAM, while Lupin will be responsible for manufacturing the same, under the agreement, it said on Monday. Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). It is used in treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion, Diabetic Macular Edema, Diabetic Retinopathy and Myopic Choroidal Neovascularization, Lupin said. 'Our intent is to transform the landscape of retinal care in Latin America, ensuring access to advanced therapies that improve the quality of life of patients,' Cyrus Karkaria, president – Biotechnology, Lupin, said in a release. Chief Strategy Officer at SteinCares Sebastian Katz said the company has consistently been the first to market products from highly regulated markets across several countries in the region. The partnership with Lupin strengthens its portfolio and reinforces SteinCares' position as a biosimilar powerhouse in Latin America.
Time of India
26-05-2025
- Business
- Time of India
Lupin inks licensing deal to supply biosimilar ranibizumab in Latin America
Drug maker Lupin on Monday said it has entered into a licence and supply agreement with SteinCares for commercialisation of biosimilar ranibizumab across Latin America , excluding Mexico and Argentina. Under the terms of the agreement, SteinCares will handle all regulatory filings, registrations and commercialisation of Ranibizumab in Latin America, while Lupin will be responsible for manufacturing the same, the Mumbai-based drug maker said in a statement. Ranibizumab is a recombinant humanised IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Myopic Choroidal Neovascularization (mCNV). by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Free P2,000 GCash eGift UnionBank Credit Card Apply Now Undo Also Read: Lupin partners with Honeywell for usage of propellant for inhalers "Our intent is to transform the landscape of retinal care in Latin America, ensuring access to advanced therapies that improve the quality of life of patients," Lupin President Biotechnology Cyrus Karkaria said. Live Events Shares of Lupin were trading 0.32% down at ₹1,972.80 apiece on BSE.
Business Standard
26-05-2025
- Business
- Business Standard
Lupin enters into license and supply agreement with SteinCares
For commercialization of Lupin's biosimilar ranibizumab across Latin America Lupin has entered into a license and supply agreement with SteinCares, a leading specialty healthcare company in Latin America, for commercialization of Lupin's biosimilar ranibizumab across Latin America excluding Mexico and Argentina. Under the terms of the agreement, SteinCares will handle all regulatory filings, registrations and commercialization of Ranibizumab in LATAM, while Lupin will be responsible for manufacturing the same. Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Myopic Choroidal Neovascularization (mCNV).
Yahoo
15-05-2025
- Health
- Yahoo
Age-Related Macular Degeneration (AMD) Market Forecast Report and Company Analysis 2025-2033 Featuring Hoffmann - La Roche, Bayer, Abbvie, GSK, Novartis, Regeneron Pharma, Bausch, Alimera Science
The aging population, rising rates of lifestyle-related risk factors, improved diagnostic tools, more awareness, and the creation of novel AMD treatments and therapies are the main factors propelling the Age-Related Macular Degeneration (AMD) market. Age-Related Macular Degeneration (AMD) Market Dublin, May 15, 2025 (GLOBE NEWSWIRE) -- The "Age-Related Macular Degeneration (AMD) Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to Macular Degeneration (AMD) Market is expected to reach US$ 20.88 billion by 2033 from US$ 11.42 billion in 2024, with a CAGR of 6.94% from 2025 to 2033 In affluent societies, age-related macular degeneration (AMD) is the primary cause of blindness in older adults. It is an age-related eye condition that gradually impairs the central vision required for reading, driving, facial recognition, and color vision. As AMD worsens, central vision is lost, impairing quality of life by preventing many patients from reading, writing, or recognizing color and detail. Recent advancements in genetic technologies have led to the discovery of several variants that have been demonstrated to have distinct relationships with AMD, despite the fact that the precise functional pathophysiology of AMD is still macula, the core portion of the retina, gradually degenerates in age-related macular degeneration, resulting in central vision loss. Based on its clinical characteristics, such as drusen, aberrant pigmentation, atrophy of the retinal pigment epithelium (RPE), and exudative choroidal neovascularization (CNV), age-related macular degeneration can be categorized as early, intermediate, or late. Another way to describe age-related macular degeneration is as wet (exudative or neovascular) or dry (atrophic or non-neovascular).The market is expected to be primarily driven by the introduction of new products, a robust product pipeline, and an increase in the prevalence of AMD. According to the Population Reference Bureau, the number of Americans 65 and older is expected to increase by 47%, from 58 million in 2022 to 82 million in 2050. Today, the U.S. population is older than it has ever of the main elements driving category expansion is the aging population. About 200,000 new cases of wet AMD are discovered in North America each year, according to Genentech. Wet AMD causes 90 percent of legal blindness but only accounts for about 10 percent of events. Because of the unchecked proliferation of new blood vessels in the eye, which results in fluid leaking into the macula, this advanced variety can cause rapid and severe vision Drivers for the Age-Related Macular Degeneration (AMD) Market Innovative Treatment OptionsThe management of age-related macular degeneration (AMD) has changed dramatically as a result of the introduction of novel medications, including as anti-VEGF (vascular endothelial growth factor) therapy. These therapies have been shown to stabilize or enhance vision in a large number of patients by preventing aberrant blood vessel formation in the retina, which is a defining feature of wet AMD. Furthermore, by focusing on the genetic defects that cause AMD, advances in gene therapy hold the promise of treating the disease's underlying causes. The market is expanding as a result of these new treatment options, which can delay the course of AMD and enhance patients' quality of life. It is anticipated that more ground-breaking treatments will surface as research progresses, increasing the range of available treatments and improving patient AwarenessGrowing public knowledge of age-related macular degeneration (AMD) is a major factor in the market's growth. The public is being educated about the symptoms, risk factors, and significance of early diagnosis through awareness programs run by patient advocacy organizations, healthcare organizations, and ophthalmology experts. People are more inclined to seek early screening as they become more knowledgeable about the illness, which can result in earlier therapies that can improve outcomes. More people are identifying AMD in its early stages thanks to better access to healthcare, especially in poorer nations. The market for AMD is developing as a result of increased awareness and proactive healthcare strategies, which are driving up demand for diagnostic and treatment Healthcare InvestmentsNew and better treatments for Age-Related Macular Degeneration (AMD) are being developed more quickly thanks to increased funding for ophthalmology and retinal research. More research into improved diagnostic methods, cutting-edge treatments, and even cures for AMD is being made possible by increased funding from the public and commercial sectors. Additionally, this investment is supporting clinical trials for potential medications and therapies that could provide better treatments for both wet and dry forms of AMD. The market for AMD is seeing the introduction of innovative treatments and diagnostic tools due to technological breakthroughs and an increasing emphasis on retinal health. These developments will ultimately improve patient care and propel market in the Age-Related Macular Degeneration (AMD) Market High Treatment CostsPatients may need repeated injections over long periods of time, and treatments for Age-Related Macular Degeneration (AMD), particularly anti-VEGF medications, can be costly. Both patients and healthcare systems may experience severe financial hardship as a result of these exorbitant expenses, especially in areas with low and moderate incomes where access to cutting-edge treatments may be of Early DiagnosisIn its early stages, patients may not detect any signs of age-related macular degeneration (AMD), which frequently develops slowly. Because of this, many people wait until they have experienced severe vision loss before seeking medical help. Early detection can be difficult due to the disease's sluggish progression, and by the time patients receive a diagnosis, the illness is frequently well advanced. Company Analysis: Overview, Key Persons, Recent Development & Strategies, Financial Insights Hoffmann - La Roche Ltd. Bayer AG Abbvie GSK Plc Novartis AG Regeneron Pharmaceuticals Bausch Health Companies Inc. Alimera Sciences Inc. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $11.42 Billion Forecasted Market Value (USD) by 2033 $20.88 Billion Compound Annual Growth Rate 6.9% Regions Covered Global Key Topics Covered: 1. Introduction2. Research Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Global Age-Related Macular Degeneration Market6. Market Share6.1 Disease Type6.2 Product6.3 Distribution Channel6.4 Country7. Disease Type7.1 Dry Age-Related Macular Degeneration Market7.2 Wet Age-Related Macular Degeneration Market8. Product8.1 Eylea8.2 Lucentis8.3 Beovu8.4 Others9. Distribution Channel9.1 Hospital Pharmacy9.2 Specialty Pharma9.3 Online Pharmacy10. Country10.1 North America10.1.1 United States10.1.2 Canada10.2 Europe10.2.1 France10.2.2 Germany10.2.3 Italy10.2.4 Spain10.2.5 United Kingdom10.2.6 Belgium10.2.7 Netherlands10.2.8 Turkey10.3 Asia Pacific10.3.1 China10.3.2 Japan10.3.3 India10.3.4 Australia10.3.5 South Korea10.3.6 Thailand10.3.7 Malaysia10.3.8 Indonesia10.3.9 New Zealand10.4 Latin America10.4.1 Brazil10.4.2 Mexico10.4.3 Argentina10.5 Middle East & Africa10.5.1 South Africa10.5.2 Saudi Arabia10.5.3 UAE11. Porter's Five Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Age-Related Macular Degeneration (AMD) Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
